


Financial and Non-Financial Highlights


Astellas achieved double-digit growth in sales and profit year on year in fiscal 2015, fueled by global growth of products in the oncology field and the urology overactive bladder (OAB) franchise, the Company's growth drivers.

Sales




Consolidated sales in fiscal 2015 increased by 10.1% year on year to ¥1,372.7 billion, supported by growing sales of prostate cancer treatment XTANDI, OAB treatments (Vesicare and Betanis/Myrbetriq/BETMIGA) and other products.

Core Operating Profit / Core Operating Margin




Core operating profit in fiscal 2015 increased by 23.5% year on year to ¥267.5 billion. The core operating margin was 19.5%. Following on from the previous fiscal year, Astellas achieved double-digit growth in core operating profit, along with a steady increase in the core operating margin in line with the strategic plan.

R&D Expenses / R&D Ratio per Sales




Research and development (R&D) expenses in fiscal 2015 rose by 9.2% year on year to ¥225.7 billion, which, in addition to increased expenses related to progress on development projects, was partly due to the foreign exchange rate impact. The ratio of R&D expenses to sales was 16.4%.

Core Profit for the Year




In fiscal 2015, core profit for the year increased by 29.7% year on year to ¥198.8 billion, tracking the increase in core operating profit.

Free Cash Flows



Free cash flow in fiscal 2015 increased mainly due to an increase in profit before tax, and proceeds from the transfer of the global dermatology business, despite an increase in net cash flows used in investing activities.


ROE*



In fiscal 2015, ROE increased to 15.0%. Astellas aims to maintain and improve this level over the medium to long term by maximizing earnings capabilities and enhancing capital efficiency.

* Return on equity


Dividends per Share*1 / DOE*2



Astellas strives to increase dividend payments stably and continuously based on medium- to long-term profit growth. In fiscal 2015, the annual dividend was ¥32 per share, representing a DOE of 5.4%.


*1 Calculated based on retrospective adjustment for a stock split of common stock at a ratio of 5 for 1 conducted on April 1, 2014.
*2 Dividend on equity attributable to owners of the parent

Number of Employees by Region




The number of employees increased by a combined total of around 100. It increased in the Americas, EMEA and Asia & Oceania, but decreased in Japan.

Number of Employees / Female Employee Ratio / Female Manager Ratio




On a global basis, the female employee ratio was 43.5% and the female manager ratio was 32.2% in fiscal 2015. Improving female manager ratio in Japan is a particularly urgent issue for Astellas.

Energy Consumption / Greenhouse Gas Emissions



In fiscal 2015, greenhouse gas emissions were 185 kilotons, reflecting efforts by Astellas to reduce greenhouse gas emissions accompanying its own activities. The amount of greenhouse gas emissions accompanying electricity use at overseas production sites was reviewed against international guidelines.

Amount of Water Withdrawal



Aiming to establish a recycling-oriented society, Astellas has been striving to reduce water withdrawal. As a result, Astellas achieved its numerical target for water withdrawal in the final target year of fiscal 2015.

Definition of Financial Results on a Core Basis

We disclose our financial results under IFRS on a core basis to help provide an accurate indication of the Group's recurring profitability. Certain items reported in financial results under IFRS on a full basis that are deemed to be non-recurring items by the Company are excluded as non-core items on a core basis.

